MX2021007426A - Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. - Google Patents

Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.

Info

Publication number
MX2021007426A
MX2021007426A MX2021007426A MX2021007426A MX2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A MX 2021007426 A MX2021007426 A MX 2021007426A
Authority
MX
Mexico
Prior art keywords
compounds
imidazopyridazine
kinase
inhibitors
activin receptor
Prior art date
Application number
MX2021007426A
Other languages
English (en)
Inventor
Song Mei
Jun Pan
Liangxing Wu
Chunhong He
Wenqing Yao
Jeremy Roach
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2021007426A publication Critical patent/MX2021007426A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen compuestos de Fórmula (I), métodos para usarse los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden tales compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, como el cáncer (ver fórmula I).
MX2021007426A 2018-12-20 2019-12-19 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. MX2021007426A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782994P 2018-12-20 2018-12-20
US201962935891P 2019-11-15 2019-11-15
PCT/US2019/067403 WO2020132197A1 (en) 2018-12-20 2019-12-19 Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Publications (1)

Publication Number Publication Date
MX2021007426A true MX2021007426A (es) 2021-09-08

Family

ID=69467674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007426A MX2021007426A (es) 2018-12-20 2019-12-19 Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.

Country Status (20)

Country Link
US (2) US11459329B2 (es)
EP (1) EP3898627A1 (es)
JP (2) JP7414827B2 (es)
KR (1) KR20210116488A (es)
CN (1) CN114787160A (es)
AU (1) AU2019401649A1 (es)
BR (1) BR112021011948A2 (es)
CA (1) CA3124088A1 (es)
CL (1) CL2021001656A1 (es)
CO (1) CO2021008117A2 (es)
CR (1) CR20210336A (es)
EC (1) ECSP21044843A (es)
IL (1) IL284139A (es)
MA (1) MA54551A (es)
MX (1) MX2021007426A (es)
PE (1) PE20220277A1 (es)
PH (1) PH12021551446A1 (es)
SG (1) SG11202106582YA (es)
TW (1) TW202039502A (es)
WO (1) WO2020132197A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019401649A1 (en) * 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
AU2021288107A1 (en) 2020-06-12 2022-12-15 Incyte Corporation Imidazopyridazine compounds with activity as ALK2 inhibitors
WO2023066204A1 (zh) * 2021-10-18 2023-04-27 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321628C (zh) 2000-06-28 2007-06-20 史密斯克莱·比奇曼公司 湿磨方法
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
US7528138B2 (en) 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JP5572388B2 (ja) * 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
AU2008280135B2 (en) 2007-07-26 2012-02-23 Novartis Ag Organic compounds
CA2703037A1 (en) 2007-10-17 2009-04-23 Novartis Ag Organic compounds
WO2011008640A1 (en) 2009-07-14 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methods of increasing liver proliferation
CA2806655A1 (en) * 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
US9738636B2 (en) 2012-09-28 2017-08-22 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
KR20150081354A (ko) 2012-11-07 2015-07-13 에프. 호프만-라 로슈 아게 트라이아졸로 화합물
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
EP4141002A1 (en) 2015-11-19 2023-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
PL3394033T3 (pl) 2015-12-22 2021-05-31 Incyte Corporation Związki heterocykliczne jako immunomodulatory
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
MX2018016273A (es) 2016-06-20 2019-07-04 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3500571T (lt) 2016-08-17 2021-04-12 Children`S Hospital Medical Center Imidazo[1,2-a]piridino junginiai, juos apimančios kompozicijos, ligų gydymo būdai juos panaudojant, ir jų paruošimo būdai
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3512834A4 (en) 2016-09-14 2020-05-06 Vanderbilt University INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
CN110582493B (zh) 2016-12-22 2024-03-08 因赛特公司 作为免疫调节剂的苯并噁唑衍生物
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
JP2020511424A (ja) 2017-01-18 2020-04-16 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害としての縮合複素環式化合物
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
AU2019401649A1 (en) 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
JP2022514650A (ja) 2022-02-14
BR112021011948A2 (pt) 2021-09-08
WO2020132197A1 (en) 2020-06-25
SG11202106582YA (en) 2021-07-29
JP2024045155A (ja) 2024-04-02
CR20210336A (es) 2021-12-06
AU2019401649A1 (en) 2021-07-08
JP7414827B2 (ja) 2024-01-16
CO2021008117A2 (es) 2021-09-20
US11459329B2 (en) 2022-10-04
CN114787160A (zh) 2022-07-22
MA54551A (fr) 2021-10-27
US20220315595A1 (en) 2022-10-06
US20200199131A1 (en) 2020-06-25
PE20220277A1 (es) 2022-02-25
CA3124088A1 (en) 2020-06-25
EP3898627A1 (en) 2021-10-27
IL284139A (en) 2021-08-31
TW202039502A (zh) 2020-11-01
KR20210116488A (ko) 2021-09-27
ECSP21044843A (es) 2021-09-30
CL2021001656A1 (es) 2021-12-17
PH12021551446A1 (en) 2021-12-06

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12021551446A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
PH12015502028A1 (en) Ido inhibitors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
PH12019501324A1 (en) Pyrazolo[3,4-b]pyridines and imidazo [1,5-b] pyridazines as pde1 inhibitors
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
ZA201901367B (en) Inhibition of olig2 activity
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.